Alk

ALK, a Pharmaceutical Preparation Manufacturing company headquartered in Denmark, reported its latest carbon emissions data for 2023. The company's total emissions for 2023 were approximately 69,555,000 kg CO2e. This figure includes Scope 1 emissions of approximately 5,128,000 kg CO2e and Scope 2 emissions (market-based) of approximately 360,000 kg CO2e. Scope 3 emissions were approximately 64,067,000 kg CO2e, with significant contributors including purchased goods and services (approximately 41,175,000 kg CO2e), employee commute (approximately 6,153,000 kg CO2e), and business travel (approximately 4,615,000 kg CO2e).

Looking ahead, ALK has set near-term Science-Based Targets initiative (SBTi) approved goals. The company is committed to reducing its absolute Scope 1 and Scope 2 greenhouse gas emissions by 42% by 2030, using 2022 as a baseline year. Additionally, ALK aims for 80% of its suppliers, by emissions covering purchased goods and services, capital goods, upstream transportation and distribution, business travel, and downstream transportation and distribution, to have science-based targets by 2028. This target specifically covers biogenic emissions and removals from bioenergy feedstocks.

Historical data indicates that ALK's Scope 1 and 2 emissions were approximately 4,883,000 kg CO2e in 2025, and approximately 5,492,000 kg CO2e in 2022. In 2021, Scope 1 emissions were approximately 5,801,000 kg CO2e and Scope 2 (market-based) were approximately 2,833,000 kg CO2e. For 2020, Scope 1 emissions were around 5,521,000 kg CO2e and Scope 2 (market-based) were approximately 3,020,000 kg CO2e. In 2019, Scope 1 emissions were approximately 5,479,000 kg CO2e and Scope 2 (market-based) were approximately 3,003,000 kg CO2e. The company achieved a 41% reduction in Scope 1 and Scope 2 CO2 emissions between 2019 and 2022.